111 related articles for article (PubMed ID: 10406646)
41. Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Garsky VM; Gilbert KF; Leighton JL; Carson KL; Mellin EC
J Med Chem; 1993 Dec; 36(26):4276-92. PubMed ID: 8277510
[TBL] [Abstract][Full Text] [Related]
42. Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C; Kleven M
J Med Chem; 1999 May; 42(9):1648-60. PubMed ID: 10229633
[TBL] [Abstract][Full Text] [Related]
43. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.
Santulli RJ; Kinney WA; Ghosh S; Decorte BL; Liu L; Tuman RW; Zhou Z; Huebert N; Bursell SE; Clermont AC; Grant MB; Shaw LC; Mousa SA; Galemmo RA; Johnson DL; Maryanoff BE; Damiano BP
J Pharmacol Exp Ther; 2008 Mar; 324(3):894-901. PubMed ID: 18083913
[TBL] [Abstract][Full Text] [Related]
44. Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of pyrrolopiperidinone acetic acids as CRTh2 antagonists.
Andrés M; Buil MA; Calbet M; Casado O; Castro J; Eastwood PR; Eichhorn P; Ferrer M; Forns P; Moreno I; Petit S; Roberts RS
Bioorg Med Chem Lett; 2014 Nov; 24(21):5111-7. PubMed ID: 25437503
[TBL] [Abstract][Full Text] [Related]
45. A novel pyridazinone derivative as a nonprostanoid PGI2 agonist.
Tsubaki K; Taniguchi K; Tabuchi S; Okitsu O; Hattori K; Seki J; Sakane K; Tanaka H
Bioorg Med Chem Lett; 2000 Dec; 10(24):2787-90. PubMed ID: 11133092
[TBL] [Abstract][Full Text] [Related]
46. Biphenyls as potent vitronectin receptor antagonists. Part 3: Squaric acid amides.
Urbahns K; Härter M; Albers M; Schmidt D; Stelte-Ludwig B; Brüggemeier U; Vaupel A; Keldenich J; Lustig K; Tsujishita H; Gerdes C
Bioorg Med Chem Lett; 2007 Nov; 17(22):6151-4. PubMed ID: 17910915
[TBL] [Abstract][Full Text] [Related]
47. Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists I.
Alonso JA; Andrés M; Bravo M; Buil MA; Calbet M; Castro J; Eastwood PR; Eichhorn P; Esteve C; Gómez E; González J; Mir M; Petit S; Roberts RS; Vidal B; Vidal L; Vilaseca P; Zanuy M
Bioorg Med Chem Lett; 2014 Nov; 24(21):5118-22. PubMed ID: 25437504
[TBL] [Abstract][Full Text] [Related]
48. In vivo efficacy studies of layer-by-layer nano-matrix bearing kaempferol for the conditions of osteoporosis: a study in ovariectomized rat model.
Kumar A; Gupta GK; Khedgikar V; Gautam J; Kushwaha P; Changkija B; Nagar GK; Gupta V; Verma A; Dwivedi AK; Chattopadhyay N; Mishra PR; Trivedi R
Eur J Pharm Biopharm; 2012 Nov; 82(3):508-17. PubMed ID: 22926146
[TBL] [Abstract][Full Text] [Related]
49. Discovery of DS42450411 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4-aminopyrimidine derivatives.
Fukuda T; Ishiyama T; Katagiri T; Ueda K; Muramatsu S; Hashimoto M; Aki A; Baba D; Watanabe K; Tanaka N
Bioorg Med Chem Lett; 2018 Nov; 28(20):3333-3337. PubMed ID: 30217414
[TBL] [Abstract][Full Text] [Related]
50. Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.
Borzilleri RM; Bhide RS; Barrish JC; D'Arienzo CJ; Derbin GM; Fargnoli J; Hunt JT; Jeyaseelan R; Kamath A; Kukral DW; Marathe P; Mortillo S; Qian L; Tokarski JS; Wautlet BS; Zheng X; Lombardo LJ
J Med Chem; 2006 Jun; 49(13):3766-9. PubMed ID: 16789733
[TBL] [Abstract][Full Text] [Related]
51. Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
Högberg M; Sahlberg C; Engelhardt P; Noréen R; Kangasmetsä J; Johansson NG; Oberg B; Vrang L; Zhang H; Sahlberg BL; Unge T; Lövgren S; Fridborg K; Bäckbro K
J Med Chem; 1999 Oct; 42(20):4150-60. PubMed ID: 10514285
[TBL] [Abstract][Full Text] [Related]
52. Identification of novel and orally active spiroindoline NPY Y5 receptor antagonists.
Sakamoto T; Moriya M; Haga Y; Takahashi T; Shibata T; Okamoto O; Nonoshita K; Kitazawa H; Hidaka M; Gomori A; Iwaasa H; Ishihara A; Kanatani A; Fukami T; Gao YD; Macneil DJ; Yang L
Bioorg Med Chem Lett; 2009 Mar; 19(6):1564-8. PubMed ID: 19243937
[TBL] [Abstract][Full Text] [Related]
53. Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead.
Williams TM; Stump CA; Nguyen DN; Quigley AG; Bell IM; Gallicchio SN; Zartman CB; Wan BL; Penna KD; Kunapuli P; Kane SA; Koblan KS; Mosser SD; Rutledge RZ; Salvatore C; Fay JF; Vacca JP; Graham SL
Bioorg Med Chem Lett; 2006 May; 16(10):2595-8. PubMed ID: 16527483
[TBL] [Abstract][Full Text] [Related]
54. Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405).
Hirst WD; Andree TH; Aschmies S; Childers WE; Comery TA; Dawson LA; Day M; Feingold IB; Grauer SM; Harrison BL; Hughes ZA; Kao J; Kelly MG; van der Lee H; Rosenzweig-Lipson S; Saab AL; Smith DL; Sullivan K; Rizzo SJ; Tio C; Zhang MY; Schechter LE
J Pharmacol Exp Ther; 2008 Apr; 325(1):134-45. PubMed ID: 18182558
[TBL] [Abstract][Full Text] [Related]
55. 1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.
Bromidge SM; Davies S; Duckworth DM; Forbes IT; Jones GE; Jones J; King FD; Blackburn TP; Holland V; Kennett GA; Lightowler S; Middlemiss DN; Riley GJ; Trail B; Wood MD
Bioorg Med Chem Lett; 2000 Aug; 10(16):1867-70. PubMed ID: 10969987
[TBL] [Abstract][Full Text] [Related]
56. Orally active, nonpeptide vasopressin V1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihdyro-2(1H)-quinolinone.
Ogawa H; Yamamura Y; Miyamoto H; Kondo K; Yamashita H; Nakaya K; Chihara T; Mori T; Tominaga M; Yabuuchi Y
J Med Chem; 1993 Jul; 36(14):2011-7. PubMed ID: 8393113
[TBL] [Abstract][Full Text] [Related]
57. The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists.
Bell IM; Bednar RA; Corcoran HA; Fay JF; Gallicchio SN; Johnston VK; Hershey JC; Miller-Stein CM; Moore EL; Mosser SD; Roller SA; Salvatore CA; Theberge CR; Wong BK; Blair Zartman C; Kane SA; Williams TM; Graham SL; Vacca JP
Bioorg Med Chem Lett; 2009 Aug; 19(16):4740-2. PubMed ID: 19577468
[TBL] [Abstract][Full Text] [Related]
58. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
[TBL] [Abstract][Full Text] [Related]
59. Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel.
Bilodeau MT; Balitza AE; Koester TJ; Manley PJ; Rodman LD; Buser-Doepner C; Coll KE; Fernandes C; Gibbs JB; Heimbrook DC; Huckle WR; Kohl N; Lynch JJ; Mao X; McFall RC; McLoughlin D; Miller-Stein CM; Rickert KW; Sepp-Lorenzino L; Shipman JM; Subramanian R; Thomas KA; Wong BK; Yu S; Hartman GD
J Med Chem; 2004 Dec; 47(25):6363-72. PubMed ID: 15566305
[TBL] [Abstract][Full Text] [Related]
60. Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb/IIIa receptor antagonist, DMP 802.
Mousa SA; Olson RE; Bozarth JM; Lorelli W; Forsythe MS; Racanelli A; Gibbs S; Schlingman K; Bozarth T; Kapil R; Wityak J; Sielecki TM; Wexler RR; Thoolen MJ; Slee A; Reilly TM; Anderson PS; Friedman PA
J Cardiovasc Pharmacol; 1998 Aug; 32(2):169-76. PubMed ID: 9700976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
